Advertisement

5 Questions with Robert Preti, PhD

        From the very beginning, Robert "Bob" Preti had a penchant for inspiring others. He began in the classroom, teaching as an elementary and secondary teacher, then as a professor at New York City area colleges. Bob received a Bachelor of Science degree in biology from Fordham University, and a Master of Science degree and Doctorate, both in biology, from New York University. He held several roles with the New York Blood Center from 1990 to 1997, including tissue bank director, director of hematopoietic stem cell processing, scientific director and associate investigator. From 1996 to 1999, Bob was the director of hematopoietic stem cell processing and applied research at Hackensack University Medical Center in Hackensack, N.J. He also worked as a research scientist for Advanced Tissue Sciences, where his work lead to the Dermagraft product currently marketed by Organogenesis. This interesting career path led Bob to co-founding a contract development and manufacturing organization, the highly innovative PCT Cell Therapy Services, in 1999, which he has led for its now twentyyear history. After PCT's acquisition by Hitachi Chemical in 2017, Bob's role expanded as he became responsible for development, management and oversight of the global business operations of Hitachi Chemical's regenerative medicine business unit as its General Manager. In addition, he has served in a leadership capacity for many professional organizations, including treasurer and founding member of the International Society for Cellular Therapy (ISCT). He recently completed a five-year term as a director for AABB as well as a two-and-a-half-year term as Chairman for the Alliance for Regenerative Medicine, where he previously served as Vice Chairman and co-chaired the Standards and Technology Committee. He has published and presented extensively on a variety of topics related to cellular therapies.
        To read this article in full you will need to make a payment

        Purchase one-time access:

        Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
        One-time access price info
        • For academic or personal research use, select 'Academic and Personal'
        • For corporate R&D use, select 'Corporate R&D Professionals'

        Subscribe:

        Subscribe to Cytotherapy
        Already a print subscriber? Claim online access
        Already an online subscriber? Sign in
        Institutional Access: Sign in to ScienceDirect